TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 213 filers reported holding TURNING POINT THERAPEUTICS I in Q2 2022. The put-call ratio across all filers is 3.08 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $4,127,000 | +348.6% | 54,839 | +60.0% | 0.00% | +200.0% |
| Q1 2022 | $920,000 | -83.0% | 34,272 | -69.8% | 0.00% | -66.7% |
| Q4 2021 | $5,409,000 | +133.4% | 113,403 | +225.0% | 0.00% | +200.0% |
| Q3 2021 | $2,317,000 | -51.2% | 34,889 | -42.7% | 0.00% | -66.7% |
| Q2 2021 | $4,748,000 | +19.7% | 60,861 | +45.2% | 0.00% | 0.0% |
| Q1 2021 | $3,966,000 | +22.7% | 41,919 | +58.0% | 0.00% | +50.0% |
| Q4 2020 | $3,232,000 | +87.3% | 26,529 | +34.4% | 0.00% | +100.0% |
| Q3 2020 | $1,726,000 | -22.5% | 19,746 | -42.8% | 0.00% | -50.0% |
| Q2 2020 | $2,228,000 | +110.6% | 34,497 | +45.5% | 0.00% | +100.0% |
| Q1 2020 | $1,058,000 | -37.4% | 23,713 | -12.6% | 0.00% | 0.0% |
| Q4 2019 | $1,690,000 | +218.3% | 27,133 | +92.0% | 0.00% | – |
| Q3 2019 | $531,000 | +608.0% | 14,135 | +663.2% | 0.00% | – |
| Q2 2019 | $75,000 | – | 1,852 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 2,392,297 | $291,501,000 | 6.94% |
| Burrage Capital Management LLC | 72,484 | $8,832,000 | 6.73% |
| MPM BioImpact LLC | 617,372 | $75,226,000 | 6.50% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 113,541 | $13,816,000 | 3.77% |
| Orbimed Advisors | 2,745,327 | $334,518,000 | 2.93% |
| SECTORAL ASSET MANAGEMENT INC | 257,379 | $31,362,000 | 2.21% |
| Parkman Healthcare Partners LLC | 59,377 | $7,235,000 | 1.85% |
| Nicholas Investment Partners, LP | 183,676 | $22,381,000 | 1.73% |
| EMERALD ADVISERS, LLC | 357,038 | $43,505,000 | 1.44% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 336,173 | $40,963,000 | 1.42% |